Meeting
2020 ASCO Virtual Scientific Program
Safety and efficacy of biweekly gemcitabine in combination with capecitabine (GemCap) in elderly and frail patients (pts) with resected pancreatic cancer (PC).
Authors
Nausheen Hakim
Northwell Health Cancer Institute, Lake Success, NY
Nausheen Hakim , Jeffrey Chi , Hasan Rehman , William Nealon , Gary B Deutsch , Elliot Newman , Sandeep Anantha , Gene Coppa , Danielle Deperalta , Arvind Rishi , Antonia Maloney , Linda Moriarty , Melissa H Smith , Jyothi Jose , Wasif M. Saif
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4628)
DOI
10.1200/JCO.2020.38.15_suppl.4628
Abstract #
4628
Poster Bd #
236
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Second-line chemotherapy in elderly patients with advanced pancreatic cancer: A mono-institutional retrospective experience.
First Author: Giovanni Trovato
Poster
2021 ASCO Annual Meeting
Alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) as first-line treatment for de novo metastatic pancreatic cancer (MPC): Safety and effect.
First Author: Brett A. Schroeder
Poster
2020 ASCO Virtual Scientific Program
FOLFIRINOX de-escalation in advanced pancreatic cancer (aPC): A multicenter real-life study.
First Author: Hortense Chevalier
Poster
2020 Gastrointestinal Cancers Symposium
The impact of pancreatic cancer resection in the era of effective systemic treatment.
First Author: Yaacov Richard Lawrence